---
title: "Antibody discovery platform Immunocan closes RMB250 million Series A"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/286186107.md"
description: "Shanghai-based Immunocan has successfully closed a RMB250 million Series A funding round, led by Vivo Capital, with participation from Gold Mine Multi Family Office and existing investors like Kingray Capital and TigerYeah Capital. The funds will be utilized to enhance its gene-edited animal platforms, commercialize its fully human antibody rabbit platform, develop an AI-driven antibody drug screening platform, and expand its team. Founded in 2020, Immunocan specializes in antibody discovery using gene-editing technologies and collaborates with various pharmaceutical companies globally."
datetime: "2026-05-13T02:39:17.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/286186107.md)
  - [en](https://longbridge.com/en/news/286186107.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/286186107.md)
---

# Antibody discovery platform Immunocan closes RMB250 million Series A

Shanghai-based Immunocan has closed a RMB250 million Series A round led by Vivo Capital, with participation from Gold Mine Multi Family Office and follow-on backing from existing investors including Kingray Capital and TigerYeah Capital. The company said the funds will be used to advance its gene-edited animal platforms, commercialize its fully human antibody rabbit platform, build an AI-driven antibody drug screening platform, and expand its team.

Founded in 2020, Immunocan develops antibody discovery platforms based on gene-editing technologies. The company said it has built a multi-species platform portfolio spanning mouse, alpaca, and rabbit models, while also advancing its MabAI platform for AI-based antibody generation and characterization. Immunocan added that it is already working with multiple domestic and international pharmaceutical companies, including several top global drugmakers. \[TechNode reporting\]

### Related Stocks

- [300347.CN](https://longbridge.com/en/quote/300347.CN.md)
- [560600.CN](https://longbridge.com/en/quote/560600.CN.md)
- [512290.CN](https://longbridge.com/en/quote/512290.CN.md)
- [159837.CN](https://longbridge.com/en/quote/159837.CN.md)
- [159859.CN](https://longbridge.com/en/quote/159859.CN.md)
- [588250.CN](https://longbridge.com/en/quote/588250.CN.md)
- [516500.CN](https://longbridge.com/en/quote/516500.CN.md)
- [588860.CN](https://longbridge.com/en/quote/588860.CN.md)
- [159849.CN](https://longbridge.com/en/quote/159849.CN.md)
- [516820.CN](https://longbridge.com/en/quote/516820.CN.md)
- [FBT.US](https://longbridge.com/en/quote/FBT.US.md)
- [159102.CN](https://longbridge.com/en/quote/159102.CN.md)
- [516930.CN](https://longbridge.com/en/quote/516930.CN.md)
- [562600.CN](https://longbridge.com/en/quote/562600.CN.md)
- [513290.CN](https://longbridge.com/en/quote/513290.CN.md)

## Related News & Research

- [Analyst Reiterates Buy on Microbix, Citing Temporary China Slowdown and Growing Diversified Demand](https://longbridge.com/en/news/286665358.md)
- [20:03 ETHarbour BioMed Announces Promising Preclinical Data for LET003, Its First AI-Enabled Drug Candidate](https://longbridge.com/en/news/286688082.md)
- [Manulife Singapore to offer multi-cancer blood test starting May](https://longbridge.com/en/news/286710691.md)
- [Flow Pharma U.S. Patent Application Allowed for Issuance Covering Broad-Spectrum Ebola Therapy](https://longbridge.com/en/news/287076761.md)
- [Fingerprint Cards AB Bets on Merger-Led Turnaround](https://longbridge.com/en/news/286333864.md)